20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
MICROBALANCE enables gut dysbiosis analysis, a part of the HELIXAFE prevention model, which also includes the analysis of genomic instability, chronic inflammation, and immune system imbalance. Colorectal cancer is strongly associated with a compositional change of the gut microbiota, with the occurrence of pathogens that are not physiologically present, such as Fusobacterium nucleatum, for instance. For example, obesity, a very well-known risk factor for colorectal cancer, and aging, another colorectal cancer-driving factor, are associated with gut microbiota alteration. What is more, microbiota changes are associated with diseases characterized by the presence of inflammation, and the link between microbiota, and inflammation; the immune system influences cancer development both locally and at a systemic level. MICROBALANCE allows outlining a profile that may suggest an increased risk of cancer development, an actionable biomarker for cancer prevention.
